India Faces Tariff Headwinds and Opportunities as US Trade Policy Shifts Under Trump Administration
Welcome back to India Tariff News and Tracker, your focused update on how U.S. trade policy under President Trump is affecting India and Indian-linked supply chains.
Across the global system, U.S. tariffs continue to expand in scope and severity. The Yale Budget Lab’s “State of U.S. Tariffs” analysis from April 2026 estimates that the current mix of U.S. tariffs and foreign retaliation has pushed the average effective U.S. tariff rate to roughly 11.8 percent, the highest since the early 1940s. That figure is driven largely by actions aimed at major trading partners like China, the European Union, Canada, and Mexico, but the spillovers matter greatly for India.
The Baker Botts “Trump Tariff Tracker” update of May 8, 2026, outlines a sweeping global tariff environment. Key measures include a 25 percent global tariff on certain semiconductors, new or threatened tariffs on critical minerals, and the possibility of tariffs on personal protective equipment and medical devices. For Indian exporters, this means any products feeding into global tech, EV, or medical supply chains may face indirect pressure as U.S. buyers re-evaluate sourcing, pricing, and origin strategies.
India is also implicated through the U.S. push for so‑called “secondary tariffs.” Both Baker Botts and logistics firm Dimerco report that President Trump has announced or already authorized additional duties on countries “doing business” with Iran and on countries that import Venezuelan oil. Dimerco notes that a proposed 25 percent tariff on countries dealing with Iran is aimed at economies including China, India, Turkey, Pakistan, and Armenia. If this is fully implemented and India is determined to fall within that definition, Indian-origin goods targeting the U.S. market could suddenly face steep additional duties, sector by sector, at the discretion of the administration.
At the same time, heavy U.S. tariffs on other partners are opening potential windows for Indian exporters. According to the Trump Tariff Tracker at Baker Botts, all products from the European Union now face a 25 percent U.S. tariff. There is also a 10 percent tariff on all products from China, alongside separate IEEPA-based tariffs on Chinese goods described by Dimerco, including fentanyl-related measures. These penalties squeeze EU and Chinese suppliers and may create opportunities for Indian manufacturers in sectors like pharmaceuticals, auto components, engineering goods, and IT hardware, if they can offer competitive pricing and reliable compliance with U.S. rules of origin.
However, the same sources warn that pharmaceuticals are now in the crosshairs. Baker Botts notes that pharmaceuticals face variable-rate duties tied to “most-favored-nation pricing” or onshoring agreements, and Dimerco highlights a looming 200 percent ad valorem duty on pharmaceuticals currently subject to a Section 232 national security investigation. If the United States applies these measures broadly, India’s powerhouse generic drug industry could be directly exposed to sharply higher tariffs on U.S.-bound shipments, forcing exporters to renegotiate contracts, rework supply chains, or consider joint ventures and production facilities inside the United States.
Listeners should also watch the structural changes in metals tariffs. Dimerco reports that Section 232 tariffs on steel, aluminum, and now copper-containing products have been expanded, with rates up to 50 percent on some items, and—crucially—applied on the full value of covered products, not just the metal content. For Indian steel, aluminum, and metal-intensive goods, this changes the calculus: even downstream items like machinery, auto parts, and electrical equipment can now be hit as finished products, potentially eroding India’s cost advantage.
Taken together, these shifts mean India is navigating a more volatile and politicized U.S. tariff landscape than at any time in recent decades. The direct risk is that India is pulled into U.S. “secondary” sanctions and tariffs over Iran or Venezuela, and that pharmaceuticals and metal-linked exports face sudden cost spikes. The opportunity lies in replacing now‑penalized Chinese and European suppliers—if Indian firms can move quickly, document origin clearly, and stay ahead of evolving U.S. rules.
That’s all for today’s India Tariff News and Tracker. Thank you for tuning in, and don’t forget to subscribe so you never miss an update.
This has been a quiet please production, for more check out quiet please dot ai.
For more check out https://www.quietperiodplease.com/
Avoid ths tariff fee's and check out these deals https://amzn.to/4iaM94Q